• End-to-end rAAV solutions, backed by over 12 years of viral vector expertise streamline gene therapy development from capsule optimization to scalable manufacturing processes.
• A seamless transition to GMP-ready production, delivering tailor-made, regulation-compliant AAV vectors designed for the next wave of therapeutic innovation